Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Next Previous
Trial Profile

Randomized Phase III Study of Pemetrexed + Cisplatin and Vinorelbine + Cisplatin for Completely Resected Non-squamous Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pemetrexed (Primary) ; Cisplatin; Vinorelbine
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms JIPANG; JIPANG-TR

Most Recent Events

  • 13 Sep 2022 Results of final analysis of OS in the JIPANG study is presented here presented at the 47th European Society for Medical Oncology Congress
  • 24 Jun 2020 Results of exploratory study assessing relationship between tumor mutation profiles, including TMB and clinical outcome, of pemetrexed/cisplatin versus vinorelbine /cisplatin for completely resected stage II-IIIA non-squamous non-small-cell lung cancer in JIPAN study, presented at the 111th Annual Meeting of the American Association for Cancer Research - II
  • 14 May 2020 the primary end point was changed from overall survival to recurrence-free survival because, with developments in subsequent chemotherapy, death events were too few to evaluate survival at the completion of patient accrual

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top